Zhitong Financial App News, Conn Bay (600572.SH) announced that recently, the company submitted a new drug marketing application (NNDA) to the US Food and Drug Administration (FDA) through the introduction of a licensed (license-in) cooperative product, Adneuris Therapeutics, Inc. (“Adneuris” for short, a wholly-owned subsidiary of Tris Pharma, Inc.) to the US Food and Drug Administration (FDA) to treat adults severe acute pain.

Zhitong Financial App News, Conn Bay (600572.SH) announced that recently, the company submitted a new drug marketing application (NNDA) to the US Food and Drug Administration (FDA) through the introduction of a licensed (license-in) cooperative product, Adneuris Therapeutics, Inc. (“Adneuris” for short, a wholly-owned subsidiary of Tris Pharma, Inc.) to the US Food and Drug Administration (FDA) to treat adults severe acute pain.